Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancreatic Cancer Cells to Genistein
Genistein is a natural isoflavone with pharmacological or potentially anti-tumor properties. However, the resistance of cancer cells to genistein remains a major obstacle. This study focused on the mechanism implicated in the resistance of pancreatic cancer (PC) cells to genistein and the mechanism...
Main Authors: | Tianyu Li, Tiantao Kuang, Zhaoshuo Yang, Qiqi Zhang, Wen Zhang, Yue Fan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2021.633035/full |
Similar Items
-
Regulation of human mTOR complexes by DEPTOR
by: Matthias Wälchli, et al.
Published: (2021-09-01) -
Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine
by: Fengwei Cui, et al.
Published: (2021-08-01) -
Bipartite binding and partial inhibition links DEPTOR and mTOR in a mutually antagonistic embrace
by: Maren Heimhalt, et al.
Published: (2021-09-01) -
Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
by: Saira Justin, et al.
Published: (2020-06-01) -
The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects
by: Eleni A. Karatrasoglou, et al.
Published: (2023-09-01)